ANRO Quote, Financials, Valuation and Earnings

Amgen, Inc. has a net margin of -- compared to Alto Neuroscience, Inc.'s net margin of 33.55%. Alto Neuroscience, Inc.'s return on equity of -45.08% beat Amgen, Inc.'s return on equity of 95.55%.

Alto Neuroscience, Inc. has a consensus price target of $29.25, signalling upside risk potential of 58.71%. On the other hand Amgen, Inc. has an analysts' consensus of $325.88 which suggests that it could fall by -2.12%. Given that Alto Neuroscience, Inc. has higher upside potential than Amgen, Inc., analysts believe Alto Neuroscience, Inc. is more attractive than Amgen, Inc..

Alto Neuroscience, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Amgen, Inc. has a beta of 0.451, suggesting its less volatile than the S&P 500 by 54.893%.

Alto Neuroscience, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amgen, Inc. offers a yield of 2.86% to investors and pays a quarterly dividend of $2.38 per share. Alto Neuroscience, Inc. pays -- of its earnings as a dividend. Amgen, Inc. pays out 119.05% of its earnings as a dividend.

Alto Neuroscience, Inc. quarterly revenues are --, which are smaller than Amgen, Inc. quarterly revenues of $9.6B. Alto Neuroscience, Inc.'s net income of -$14.2M is lower than Amgen, Inc.'s net income of $3.2B. Notably, Alto Neuroscience, Inc.'s price-to-earnings ratio is -- while Amgen, Inc.'s PE ratio is 25.74x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alto Neuroscience, Inc. is -- versus 5.02x for Amgen, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

CEL-SCI Corp. has a net margin of -- compared to Alto Neuroscience, Inc.'s net margin of --. Alto Neuroscience, Inc.'s return on equity of -45.08% beat CEL-SCI Corp.'s return on equity of -266.61%.

Alto Neuroscience, Inc. has a consensus price target of $29.25, signalling upside risk potential of 58.71%. On the other hand CEL-SCI Corp. has an analysts' consensus of $42.50 which suggests that it could grow by 802.34%. Given that CEL-SCI Corp. has higher upside potential than Alto Neuroscience, Inc., analysts believe CEL-SCI Corp. is more attractive than Alto Neuroscience, Inc..

Alto Neuroscience, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison CEL-SCI Corp. has a beta of 0.487, suggesting its less volatile than the S&P 500 by 51.259%.

Alto Neuroscience, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CEL-SCI Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alto Neuroscience, Inc. pays -- of its earnings as a dividend. CEL-SCI Corp. pays out -- of its earnings as a dividend.

Alto Neuroscience, Inc. quarterly revenues are --, which are smaller than CEL-SCI Corp. quarterly revenues of --. Alto Neuroscience, Inc.'s net income of -$14.2M is lower than CEL-SCI Corp.'s net income of -$5.7M. Notably, Alto Neuroscience, Inc.'s price-to-earnings ratio is -- while CEL-SCI Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alto Neuroscience, Inc. is -- versus -- for CEL-SCI Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly & Co. has a net margin of -- compared to Alto Neuroscience, Inc.'s net margin of 31.72%. Alto Neuroscience, Inc.'s return on equity of -45.08% beat Eli Lilly & Co.'s return on equity of 106.26%.

Alto Neuroscience, Inc. has a consensus price target of $29.25, signalling upside risk potential of 58.71%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,093.22 which suggests that it could grow by 1.44%. Given that Alto Neuroscience, Inc. has higher upside potential than Eli Lilly & Co., analysts believe Alto Neuroscience, Inc. is more attractive than Eli Lilly & Co..

Alto Neuroscience, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.370, suggesting its less volatile than the S&P 500 by 62.965%.

Alto Neuroscience, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly & Co. offers a yield of 0.56% to investors and pays a quarterly dividend of $1.50 per share. Alto Neuroscience, Inc. pays -- of its earnings as a dividend. Eli Lilly & Co. pays out 44.39% of its earnings as a dividend. Eli Lilly & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Alto Neuroscience, Inc. quarterly revenues are --, which are smaller than Eli Lilly & Co. quarterly revenues of $17.6B. Alto Neuroscience, Inc.'s net income of -$14.2M is lower than Eli Lilly & Co.'s net income of $5.6B. Notably, Alto Neuroscience, Inc.'s price-to-earnings ratio is -- while Eli Lilly & Co.'s PE ratio is 53.30x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alto Neuroscience, Inc. is -- versus 16.54x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer Inc. has a net margin of -- compared to Alto Neuroscience, Inc.'s net margin of 21.32%. Alto Neuroscience, Inc.'s return on equity of -45.08% beat Pfizer Inc.'s return on equity of 10.84%.

Alto Neuroscience, Inc. has a consensus price target of $29.25, signalling upside risk potential of 58.71%. On the other hand Pfizer Inc. has an analysts' consensus of $28.62 which suggests that it could grow by 14.08%. Given that Alto Neuroscience, Inc. has higher upside potential than Pfizer Inc., analysts believe Alto Neuroscience, Inc. is more attractive than Pfizer Inc..

Alto Neuroscience, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.457, suggesting its less volatile than the S&P 500 by 54.271%.

Alto Neuroscience, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer Inc. offers a yield of 6.86% to investors and pays a quarterly dividend of $0.43 per share. Alto Neuroscience, Inc. pays -- of its earnings as a dividend. Pfizer Inc. pays out 119.94% of its earnings as a dividend.

Alto Neuroscience, Inc. quarterly revenues are --, which are smaller than Pfizer Inc. quarterly revenues of $16.7B. Alto Neuroscience, Inc.'s net income of -$14.2M is lower than Pfizer Inc.'s net income of $3.6B. Notably, Alto Neuroscience, Inc.'s price-to-earnings ratio is -- while Pfizer Inc.'s PE ratio is 14.62x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alto Neuroscience, Inc. is -- versus 2.28x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.